KRTX - Karuna Therpeutics submits NDA for schizophrenia drug
2023-09-28 10:11:57 ET
More on Karuna Therapeutics
- Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT
- Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade)
- Wells Fargo starts Karuna at overweight, cites schizophrenia drug candidate
- Seeking Alpha’s Quant Rating on Karuna Therapeutics
For further details see:
Karuna Therpeutics submits NDA for schizophrenia drug